| 1 |
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Edward B. Garon et al. · New England Journal of Medicine
Open access |
19 Apr 2015 |
6,312 |
| 2 |
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Omid Hamid et al. · New England Journal of Medicine
Open access |
2 Jun 2013 |
3,425 |
| 3 |
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Alexander Edward Dela Cruz Drilon et al. · New England Journal of Medicine
Open access |
21 Feb 2018 |
2,827 |
| 4 |
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Mark E. Davis, Jonathan E. Zuckerman, Chung Hang Jonathan Choi et al. · Nature
Open access |
21 Mar 2010 |
2,506 |
| 5 |
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al. · The Lancet
|
14 Jul 2014 |
1,779 |
| 6 |
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
Corey Jay Langer, Shirish M. Gadgeel, Hossein Borghaei et al. · The Lancet Oncology
Open access |
12 Oct 2016 |
1,407 |
| 7 |
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
Edward B. Garon, Matthew D. Hellmann, Naiyer A. Rizvi et al. · Journal of Clinical Oncology
Open access |
2 Jun 2019 |
1,210 |
| 8 |
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Antoni Ribas et al. · JAMA
Open access |
19 Apr 2016 |
1,081 |
| 9 |
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
Omid Hamid, Caroline Robert, ADIL I. DAUD et al. · Annals of Oncology
Open access |
29 Jan 2019 |
961 |
| 10 |
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Amita Patnaik et al. · Clinical Cancer Research
|
14 May 2015 |
813 |
| 11 |
Efficacy of Selpercatinib in RET -Altered Thyroid Cancers
Lori J. Wirth et al. · New England Journal of Medicine
Open access |
26 Aug 2020 |
801 |
| 12 |
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors
Amita Patnaik et al. · Cancer Discovery
|
23 May 2016 |
773 |
| 13 |
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
Branimir Ivan Sikic et al. · Journal of Clinical Oncology
Open access |
27 Feb 2019 |
605 |
| 14 |
First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
Timothy Anthony Yap, Yan Li, Amita Patnaik et al. · Journal of Clinical Oncology
|
25 Oct 2011 |
545 |
| 15 |
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
Vicky Makker, Drew Warren Rasco, Nicholas J. Vogelzang et al. · The Lancet Oncology
Open access |
26 Mar 2019 |
482 |
| 16 |
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
Matthew Hiram Taylor, Chung‐Han Lee, Vicky Makker et al. · Journal of Clinical Oncology
Open access |
21 Jan 2020 |
459 |
| 17 |
The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
Toshio Shimizu, Anthony W. Tolcher, Kyriakos P. Papadopoulos et al. · Clinical Cancer Research
|
19 Jan 2012 |
434 |
| 18 |
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
Ryan Joseph Sullivan et al. · Cancer Discovery
|
15 Dec 2017 |
430 |
| 19 |
Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA
Jonathan E. Zuckerman, Ismael Gritli, Anthony W. Tolcher et al. · Proceedings of the National Academy of Sciences
Open access |
21 Jul 2014 |
425 |
| 20 |
A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer
Manuel M. Hidalgo, Elizabeth M. Bruckheimer, N.V. Rajeshkumar et al. · Molecular Cancer Therapeutics
Open access |
15 Jun 2011 |
410 |
| 21 |
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
Vincenzo Mazzaferro, Bassel F. El‐Rayes, Michele Droz Dit Busset et al. · British Journal of Cancer
Open access |
7 Nov 2018 |
385 |
| 22 |
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation
Adrian Gerold Sacher et al. · New England Journal of Medicine
Open access |
23 Aug 2023 |
317 |
| 23 |
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS G12C Solid Tumors (KRYSTAL-1)
Sai‐Hong Ignatius Ou, Pasi Antero Janne, Ticiana A.B. Leal et al. · Journal of Clinical Oncology
Open access |
15 Feb 2022 |
316 |
| 24 |
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Richard Wayne Joseph et al. · Clinical Cancer Research
Open access |
23 Apr 2018 |
314 |
| 25 |
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
Toni K. Choueiri, Todd Michael Bauer, Kyriakos P. Papadopoulos et al. · Nature Medicine
Open access |
22 Apr 2021 |
309 |
| 26 |
An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma
Yotam Drier, Matthew J. Cotton, Kaylyn E. Williamson et al. · Nature Genetics
Open access |
Feb 2016 |
303 |
| 27 |
First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆
Jiaxin Niu, Corinne Maurice‐Dror, D.H. Lee et al. · Annals of Oncology
Open access |
17 Nov 2021 |
298 |
| 28 |
Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors
Anthony W. Tolcher, Wells A. Messersmith, Stanislaw M. Mikulski et al. · Journal of Clinical Oncology
Open access |
24 Apr 2012 |
280 |
| 29 |
A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors
Shahneen Kaur Sandhu, Kyri P. Papadopoulos, Peter C.C. Fong et al. · Cancer Chemotherapy and Pharmacology
|
5 Feb 2013 |
273 |
| 30 |
PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients
Aung Naing et al. · Cancer Cell
Open access |
Nov 2018 |
256 |
| 31 |
Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas
Sant P. Chawla, Arthur P. Staddon, Laurence H. Baker et al. · Journal of Clinical Oncology
Open access |
8 Nov 2011 |
248 |
| 32 |
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
Amita Patnaik et al. · Annals of Oncology
Open access |
26 Sep 2016 |
241 |
| 33 |
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
Rina Hui, Edward B. Garon, J.W. Goldman et al. · Annals of Oncology
Open access |
7 Feb 2017 |
240 |
| 34 |
Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
David Wesley Craig et al. · Molecular Cancer Therapeutics
|
20 Nov 2012 |
226 |
| 35 |
Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study
Maeve Aine Lowery et al. · The Lancet. Gastroenterology & hepatology
Open access |
9 Jul 2019 |
223 |
| 36 |
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP -Deleted Cancer
Lars D. Engstrom et al. · Cancer Discovery
Open access |
8 Aug 2023 |
219 |
| 37 |
First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors
Kyriakos P. Papadopoulos, Larry Gluck, Lainie P. Martin et al. · Clinical Cancer Research
|
27 Jun 2017 |
217 |
| 38 |
Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors
Robert H. Vonderheide, Jennifer M. Burg, Rosemarie Mick et al. · OncoImmunology
Open access |
2013 |
205 |
| 39 |
Recent Developments in Amber Biomolecular Simulations
David Andrew Case et al. · Journal of Chemical Information and Modeling
Open access |
29 Jul 2025 |
204 |
| 40 |
24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer
Hossein Borghaei, Corey Jay Langer, Shirish M. Gadgeel et al. · Journal of Thoracic Oncology
Open access |
20 Aug 2018 |
200 |
| 41 |
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study
Funda Meric‐Bernstam et al. · The Lancet Oncology
Open access |
15 Nov 2022 |
198 |
| 42 |
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
L. Rhoda Molife, Yan Li, Joanna Vitfell-Rasmussen et al. · Journal of Hematology & Oncology
Open access |
3 Jan 2014 |
192 |
| 43 |
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study
Chung‐Han Lee et al. · The Lancet Oncology
Open access |
15 Jun 2021 |
189 |
| 44 |
Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC
Mark Magdi Awad, Shirish M. Gadgeel, Hossein Borghaei et al. · Journal of Thoracic Oncology
Open access |
15 Oct 2020 |
187 |
| 45 |
Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation
James Chih‐Hsin Yang, Shirish M. Gadgeel, Lecia VanDam Sequist et al. · Journal of Thoracic Oncology
Open access |
4 Dec 2018 |
185 |
| 46 |
Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study
Natasha B. Leighl, Matthew David Hellmann, Rina Hui et al. · The Lancet Respiratory Medicine
|
12 Mar 2019 |
182 |
| 47 |
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
Aditya Bardia, Ian E. Krop, Takahiro Kogawa et al. · Journal of Clinical Oncology
Open access |
23 Apr 2024 |
178 |
| 48 |
Antibody drug conjugates: lessons from 20 years of clinical experience
Anthony W. Tolcher · Annals of Oncology
Open access |
13 Oct 2016 |
171 |
| 49 |
Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody
James J. Harding, Víctor Moreno, Yung‐Jue Bang et al. · Clinical Cancer Research
Open access |
29 Jan 2021 |
165 |
| 50 |
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma
William D. Tap, Victor Manuel Villalobos, Gregory Michael Cote et al. · Journal of Clinical Oncology
Open access |
25 Mar 2020 |
165 |